The Stockholm-based company said it will use the funds to develop its metabolism-based liquid biopsy platform.
The test, which is in development using perspiration as a sample, has shown promising performance in a preliminary study.
By examining metagenomic data of bacterial species in a patient's gut, the researchers aim to improve diagnosis and long-term nutritional intervention and treatment.
Researchers in Nigeria are developing a handheld diagnostic device for identifying high-risk colorectal cancer patients in low-resource environments.
The firm will use the financing to commercialize a test that utilizes metabolomic and DNA biomarkers to characterize obesity and guide weight loss.
A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.
A new study suggests binding proteins that target glucose or asparagine can be used in combination with cytolysin A-based nanopores to electrically detect the metabolites.
The handheld device uses CMOS technology for multiplexed measurement of disease-linked metabolites and could prove useful for inexpensive POC testing.
The grants include funding for five new clinical sites, a new metabolomics core, and increased model organism capabilities.
The company published data from a 1,102-patient trial that found that amino acid markers could be useful for diagnosing the condition in a subset of patients.